 |
|
Correlation of Clinical and Immunologic States in Multiple Sclerosis
M. Ray Mickey, PhD;
George W. Ellison, MD;
John L. Fahey, MD;
Dewey J. Moody, PhD;
Lawrence W. Myers, MD
Arch Neurol. 1987;44(4):371-375.
Abstract
• Cyclophosphamide was administered to 14 patients with chronic progressive multiple sclerosis on an intermittent escalating dosage schedule adjusted to maintain numbers of peripheral blood B lymphocytes and helper/inducer (CD4) T cells below the fifth percentile of the normal population. Peripheral blood B cells, T cells, suppressor/cytotoxic (CD8) T cells, CD4 cells, and FcR+-bearing cell numbers and percentages were monitored at one-week to two-week intervals. Clinical status was assessed by neurologic examinations at approximately four-week intervals. Regression analysis revealed a statistically significant correlation between changes in immunologic status and changes in clinical state. The immunologic changes preceded the neurologic changes. Increases in percent of CD8 cells and decreases in percent of CD4 cells forecast improved clinical course. These findings, coupled with other studies, strongly suggest a pathogenetic role for helper and suppressor T cells in the production of clinical signs of multiple sclerosis.
Author Affiliations
From the Department of Biomathematics (Dr Mickey), the Department of Neurology, Reed Neurological Research Center (Drs Ellison and Myers), and the Medical Immunology Laboratory, CIRID, Department of Microbiology and Immunology (Drs Fahey and Moody), UCLA School of Medicine.
Footnotes
Accepted for publication Jan 9, 1987.
Reprint requests to the Department of Neurology, UCLA School of Medicine, Reed Neurological Research Center, 710 Westwood Plaza, Los Angeles, CA 90024 (Dr Myers).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Weiner and Cohen
Mult Scler 2002;8:142-154.
ABSTRACT
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol et al.
Mult Scler 1999;5:403-409.
ABSTRACT
|
